GlassScriptPhysician profile
Keri P Johnson
NPI 1558316034
$2,407.07
in general payments reported to CMS, 2019-2025
29 companies · $396 in 2025
The $396 reported for 2025 was more than what 90% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $144 · 2021: $355 · 2022: $298 · 2023: $512 · 2024: $541 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,449.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $342.19 | 2021-2025 | Azstarys |
| Glaxosmithkline, LLC. | $323.63 | 2019-2025 | Bexsero, Penmenvy, Rotarix |
| Cranial Technologies, INC | $256.11 | 2022-2025 | Doc Band |
| Ironshore Pharmaceuticals INC. | $166.40 | 2019-2024 | Jornay Pm |
| Sanofi Pasteur INC. | $164.41 | 2021-2024 | |
| Sobi, INC | $137.79 | 2019-2023 | |
| Pfizer INC. | $122.31 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $121.91 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $106.93 | 2020-2025 | Gardasil 9, M-M-R II, Vaxneuvance |
| Phadia US INC. | $81.52 | 2023-2025 | Immunocap |
| Takeda Pharmaceuticals U.S.A., INC. | $74.92 | 2021-2022 | |
| Tris Pharma INC | $58.54 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $53.18 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $52.02 | 2021 | |
| Shire North American Group INC | $42.80 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $42.25 | 2024 | |
| Kaleo, INC. | $29.35 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $24.18 | 2024 | Strensiq |
| Vertical Pharmaceuticals, LLC | $23.91 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $23.09 | 2022 | |
| Alk-Abello, INC | $22.43 | 2025 | Neffy |
| Neos Therapeutics, LP | $21.53 | 2020 | |
| Neurelis, INC. | $20.66 | 2024 | Valtoco |
| Biogen, INC. | $20.02 | 2023 | Spinraza |
| Abbvie INC. | $17.34 | 2024 | |
| Lilly USA, LLC | $15.11 | 2025 | Mounjaro |
| Kowa Pharmaceuticals America, INC. | $14.52 | 2024 | Zoryve |
| Exeltis, USA INC. | $14.28 | 2023 | Slynd |
| Rhodes Pharmaceuticals L.P. | $13.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keri Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.